Calquence Archives -

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

Phil Taylor AstraZeneca, Boehringer Ingelheim, Calquence, Eli Lilly, Kyowa Kirin, NHS, nintedanib, Olumiant, Oncology, Poteligeo, Scotland, Scottish Medicines Consortium, Servier 0 Comment

A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

https://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/

News/ News/ Oncology

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

Phil Taylor AbbVie, AstraZeneca, BeiGene, Brukinsa, Calquence, chronic lymphocytic leukaemia, Haematology, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

https://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/

Market Access/ News/ News

NICE backs AZ’s Calquence for new use in leukaemia

Phil Taylor AstraZeneca, Calquence, cholesterol, chronic lymphocytic leukaemia, Daiichi Sankyo, NHS, NICE, Nilemdo 0 Comment

AstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS

NICE backs AZ’s Calquence for new use in leukaemia

https://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/

News/ News/ Oncology

AZ says Calquence is a safer drug than Imbruvica

Phil Taylor AbbVie, AstraZeneca, BTK inhibitor, Calquence, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson, Oncology 0 Comment

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment

AZ says Calquence is a safer drug than Imbruvica

https://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/

News/ News/ News/ Patients/ R&D

AZ, Lilly join efforts to develop drugs for COVID-19

Phil Taylor AstraZeneca, Calquence, clinical trial, coronavirus, Eli Lilly, Olumiant 0 Comment

AstraZeneca and Eli Lilly have joined the ranks of drugmakers around the world trying to repurpose existing drugs

AZ, Lilly join efforts to develop drugs for COVID-19

https://pharmaphorum.com/news/az-lilly-join-efforts-to-develop-drugs-for-covid-19/

News/ News/ Oncology

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

Phil Taylor AbbVie, AstraZeneca, Calquence, chronic lymphocytic leukaemia, Haematology, Imbruvica, Johnson & Johnson 0 Comment

AstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence

ASH19: AZ’s Calquence throws gauntlet down to Imbruvica

https://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/

Market Access/ News/ News

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

Phil Taylor AbbVie, AstraZeneca, BeiGene, Brukinsa, BTK inhibitor, Calquence, chronic lymphocytic leukaemia, Imbruvica, Johnson & Johnson 0 Comment

AbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from

FDA nod for AZ’s Calquence sets up new Imbruvica showdown

https://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/

News/ News/ Oncology

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

George Underwood AstraZeneca, Calquence, chronic lymphocytic leukaemia, CLL, Lynparza, Merck & Co, MSD, ovarian cancer, PARP 0 Comment

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment

https://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/

News/ News/ Oncology

AstraZeneca ends another Calquence trial early

George Underwood AstraZeneca, Calquence, chronic lymphocytic leukaemia 0 Comment

For the second time in the space of a month AstraZeneca has stopped a trial of its chronic

AstraZeneca ends another Calquence trial early

https://pharmaphorum.com/news/astrazeneca-ends-another-calquence-trial-early/

Trending

Calquence

Login